SOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /CNW/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on March 5, 2025 (the "Meeting").
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
